Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Cancer Chemother Pharmacol. 2012 Mar;69(3):723-31. doi: 10.1007/s00280-011-1752-3. Epub 2011 Oct 13.
MicroRNAs (miRNAs) are short non-coding RNA molecules, which post-transcriptionally regulate genes expression and play crucial roles in diverse biological processes. Recent studies have shown that dysregulation of miRNAs might modulate the resistance of cancer cells to anti-cancer drugs, yet the modulation mechanism is not fully understood. We aimed to investigate the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines.
miRNA Quantitative real-time PCR was used to detect the different miRNA expression levels between drug resistant and parental cancer cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to test the drug-resistant phenotype changes in cancer cells via over or downregulation of miRNAs. Dual-luciferase activity assay was used to verify the target genes of miRNAs. Western blot analysis and apoptosis assay were used to elucidate the mechanism of miRNAs on modulating drug resistance in cancer cells.
miR-200bc/429 cluster was downregulated, while BCL2 and XIAP were upregulated in both MDR SGC7901/VCR (vincristine) and A549/CDDP (cisplatin) cells, compared with the parental SGC7901 and A549 cells, respectively. Overexpression of miR-200bc/429 cluster sensitized SGC7901/VCR and A549/CDDP cells to anti-cancer drugs, respectively. Both BCL2 and XIAP 3'-UTR reporters constructed in MDR cells suggested that BCL2 and XIAP were the common target genes of the miR-200bc/429 cluster. Enforced miR-200bc/429 cluster expression reduced BCL2 and XIAP protein level and sensitized both MDR cells to VCR-induced and CDDP-induced apoptosis, respectively.
Our findings first suggest that miR-200bc/429 cluster could play a role in the development of MDR in both gastric and lung cancer cell lines, at least in part by modulation of apoptosis via targeting BCL2 and XIAP.
MicroRNAs(miRNAs)是短的非编码 RNA 分子,可在后转录水平上调节基因表达,并在多种生物学过程中发挥关键作用。最近的研究表明,miRNAs 的失调可能调节癌细胞对抗癌药物的耐药性,但调节机制尚不完全清楚。我们旨在研究 miRNAs 在人胃癌和肺癌细胞系多药耐药(MDR)发展中的可能作用。
采用 miRNA 定量实时 PCR 检测耐药和亲本癌细胞之间不同 miRNA 表达水平。通过 miRNA 的过表达或下调,MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐)测定法检测癌细胞耐药表型变化。双荧光素酶活性测定法用于验证 miRNA 的靶基因。Western blot 分析和凋亡测定法用于阐明 miRNA 调节癌细胞耐药性的机制。
miR-200bc/429 簇在 MDR SGC7901/VCR(长春新碱)和 A549/CDDP(顺铂)细胞中下调,而 BCL2 和 XIAP 上调,与亲本 SGC7901 和 A549 细胞相比。miR-200bc/429 簇的过表达分别使 SGC7901/VCR 和 A549/CDDP 细胞对抗癌药物敏感。在 MDR 细胞中构建的 BCL2 和 XIAP 3'-UTR 报告基因均表明 BCL2 和 XIAP 是 miR-200bc/429 簇的共同靶基因。强制表达 miR-200bc/429 簇可降低 BCL2 和 XIAP 蛋白水平,并分别使两种 MDR 细胞对 VCR 诱导的和 CDDP 诱导的凋亡敏感。
我们的研究结果首次表明,miR-200bc/429 簇可能在胃癌和肺癌细胞系的 MDR 发展中发挥作用,至少部分通过调节 BCL2 和 XIAP 介导的凋亡。